🏢 Company Intelligence
What They Do
Twist Bioscience manufactures synthetic DNA on a proprietary silicon-based platform that miniaturizes oligonucleotide synthesis, enabling high-throughput, low-cost production of genes, oligo pools, and variant libraries. Its products serve drug discovery, diagnostics, agriculture, industrial chemicals, academic research, and DNA-based data storage customers.
Why FSI Keeps Surfacing This Company
Twist's signal density is driven by an expanding patent portfolio around silicon DNA synthesis and enzymatic methods, frequent citations across antibody discovery and NGS target enrichment research, and high-profile partnerships with pharma (e.g., Astellas, Boehringer Ingelheim) and biosecurity/government programs. Commercial momentum—accelerating revenue growth, gross margin expansion, and a divestiture sharpening focus on core synbio—keeps it surfacing across multiple signal vectors.
Recent Developments
Twist reported strong FY2025 revenue growth with meaningful gross margin improvement and reiterated a path to adjusted EBITDA breakeven, while scaling its Express Genes and library synthesis capacity at the Wilsonville factory. It also advanced its Biopharma antibody discovery business and continued spinning down the capital-intensive DNA data storage subsidiary Atlas Data Storage to concentrate resources on core synthesis and biopharma.
Key Risks
Key risks include continued operating losses and cash burn pressuring the balance sheet despite margin progress, competitive threats from enzymatic DNA synthesis entrants (Ansa, DNA Script, Elegen) and incumbents like IDT, and customer concentration in biotech end-markets sensitive to funding cycles.
🔗 Technology Domains
👁️
Showcase mode.
The top 2 companies per domain will remain free. Deeper features below — AI corpus interrogation, swap reasoning, Telegram alerts — will require Premium (£70/month).
Request early access →
🚀 Premium Features — Coming Soon
Premium subscribers will get AI interrogation of the full 56,000+ article corpus, real-time Telegram alerts when this company is flagged, swap proposals with full reasoning, and the complete signal history for TWST. Subscriptions launching soon.
Request Early Access →
Not investment advice. Company intelligence is derived from publicly available data sources. It does not constitute personalised investment advice or a recommendation to buy, sell, or hold TWST. Capital at risk. Always seek independent financial advice.